Últimas noticias sobre Aeva Technologies (NASDAQ:AEVA) Bolsa

Aeva Technologies

Aeva Technologies Inc through its Frequency Modulated Continuous Wave (FMCW) sensing technology, designs a 4D LiDAR-on-chip that, along with its proprietary software applications, has the potential to enable the adoption of LiDAR across broad applications from automated driving to consumer electronics, consumer health, industrial automation, and security application. The company operates in North America, EMEA, and Asia. The company derives the majority of its revenue from North America.

Aeva Technologies Inc

Aeva Technologies, Inc. - Redeemable Warrants

WIIM

BRCC

BRC shares are trading lower after the company announced it has priced a $35 million public offering of common stock.

News

ACTU

Actuate Therapeutics Initiates Planning Of Phase 2 Trial Of Elraglusib In Children, Adolescents, And Adults With Refractory/Resistant Ewing Sarcoma

HYPR

Hyperfine shares are trading higher after the company announced the first commercial sales of its Swoop system, powered by Optive AI software.

Actuate Therapeutics Announces End Of Phase 1 Portion Of Clinical Study Evaluating Elraglusib Monotherapy Or In Combination With Irinotecan, Irinotecan Plus Temozolomide, Or With Cyclophosphamide Plus Topotecan In Pediatric Patients With Refractory Malignancies

Offerings

NioCorp Prices $45.0M Public Offering Of 13,850,000 Shares At $3.25/Share

Guidance

IQST

IQSTEL Jun. Revenue $27.3M, Up From $23.7M In May; Reports Prelim. 1H Revenue Of $128.8M

Swiss pharmaceutical giant Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) reported second-quarter 2025 earnings on Thursday and raised its full-year earnings forecast.
Quarterly sales reached $14.05 billion, almost in line with the analysts&#8217; consensus <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">estimate of $14.06 billion</a>.
Net sales <a target="_blank" href="https://www.novartis.com/news/media-releases/novartis-reports-strong-q2-double-digit-sales-growth-and-core-margin-expansion-raises-fy-2025-core-operating-income-guidance" rel="noreferrer noopener">grew</a> 12% year over year (+11% on constant currency or cc) with core operating income up 20% to $5.93 billion (+21% on constant currency).
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/07/46292859/novartis-gets-swiss-approval-for-first-malaria-drug-for-babies" rel="noreferrer noopener">Novartis Gets Swiss Approval For First Malaria Drug For Babies</a>
Sales growth driven by performance from breast cancer treatment, Kisqali ($1.18 billion, +64% cc), Entresto ($2.36 billion, +22% cc), multiple sclerosis drug, Kesimpta ($1.08 billion, +33% cc), Scemblix ($298 million, +79% cc), Leqvio ($298 million, +61% cc), and Pluvicto ($454 million, +30% cc).
Novartis reported adjusted earnings of $2.42 per share, beating the consensus of $2.38.
The company also announced a substantial share buyback program. Novartis said it is initiating a share buyback of up $10 billion to be completed by year-end 2027.
&#8220;Our robust balance sheet and confidence in our mid- and long-term growth enable us to initiate an up-to $10 billion share buyback as part of our commitment to balanced capital allocation,&#8221; stated CEO Vas Narasimhan in a statement on Thursday.
Earlier in July, Novartis released topline results from the Phase 3 GCAptAIN study evaluating Cosentyx (secukinumab) for newly diagnosed or relapsing <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">giant cell arteritis (GCA)</a>.
The study evaluated Cosentyx with a 26-week steroid taper and compared it to a placebo plus a 52-week steroid taper.&nbsp;Cosentyx did not demonstrate a statistically significant improvement in sustained remission at <a target="_blank" href="https://www.benzinga.com/news/health-care/25/07/46243947/novartis-cosentyx-fails-late-stage-giant-cell-arteritis-trial" rel="noreferrer noopener">Week 52 compared to placebo</a>.
<h2 class="wp-block-heading">Outlook</h2>
For fiscal year 2025, Novartis reaffirms that net sales will grow in the high single digits. 2025 core operating income is expected to grow in the low teens, compared to the low double <a target="_blank" href="https://www.benzinga.com/25/04/45075714/novartis-q1-earnings-beat-street-view-ceo-confident-to-deliver-upgraded-2025-guidance" rel="noreferrer noopener">digits forecasted earlier</a>.
&#8220;We continue to assume Entresto US generic entry in mid-2025 for forecasting purposes, though the timing of generic entry is subject to ongoing IP and regulatory litigation,&#8221; Novartis said in the release.
<h2 class="wp-block-heading">Management Update</h2>
In a separate announcement, Novartis provided a key leadership update: Chief Financial Officer Harry Kirsch will <a target="_blank" href="https://www.novartis.com/news/media-releases/novartis-appoints-mukul-mehta-chief-financial-officer-harry-kirsch-retires-after-22-years-company" rel="noreferrer noopener">retire</a> in March 2026, concluding an impressive 22-year tenure at the company, including 12 years in the CFO role since 2013.
He will be succeeded by Mukul Mehta, who currently serves as the company&#8217;s head of business planning and analysis, digital finance, and tax.
Price Action: NVS stock is trading lower by 1.71% to $116.35 during the premarket session at last check Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46463670/supermicro-launches-new-ai-servers-with-intel-xeon-6-chips" target="_blank" rel="noreferrer noopener">Supermicro Launches New AI Servers With Intel Xeon 6 Chips</a></li>
</ul>
Photo via Shutterstock

Biotech

Earnings

Large Cap

Health Care

Buybacks

Management

Movers

General

Novartis Trims Operating Income Outlook After Strong Q2 Performance, Initiates $10 Billion Stock Buyback

Nano Labs shares are trading higher after the company announced it has appointed a new CEO to lead the global crypto reserve strategy of its subsidiary.

Morgan Stanley analyst Kristine Liwag maintains Teledyne Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDY#NYSE">TDY</a>) with a Equal-Weight and raises the price target from $535 to $580.

Price Target

Analyst Ratings

Morgan Stanley Maintains Equal-Weight on Teledyne Technologies, Raises Price Target to $580

ATHR

Aether Holdings' Alpha Edge Media Acquires Digital Asset Research And Publication, AltcoinInvesting.co

BPMC

Trading Halt: Halt status updated at 8:45:00 AM ET: Quotation Resumption: News and Resumption Times

Morgan Stanley analyst Kristine Liwag maintains Curtiss-Wright (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CW#NYSE">CW</a>) with a Overweight and raises the price target from $405 to $550.

Morgan Stanley Maintains Overweight on Curtiss-Wright, Raises Price Target to $550

Stock Split

LCID

Lucid Files Preliminary Proxy Statement To Initiate Plan For 1-for-10 Reverse Stock Split

NUWE

Nuwellis shares are trading lower after the company announced it has terminated its REVERSE-HF clinical trial to prioritize resources and redirect investment.

INSE

Inspired Entertainment Expands Long-Term Partnership With William Hill To Deliver Comprehensive Upgrade To William Hill's Virtual Sports Offering Across Its UK Retail Estate

OKLO

Oklo shares are trading higher after the company completed the U.S. Nuclear Regulatory Commission's pre-application readiness assessment for Phase 1 of its combined license application for the Aurora Powerhouse.

Stifel analyst Jeffrey Stantial maintains Monarch Casino &amp; Resort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRI#NASDAQ">MCRI</a>) with a Hold and raises the price target from $81 to $92.

MCRI

Stifel Maintains Hold on Monarch Casino & Resort, Raises Price Target to $92

B. Riley Securities analyst Mike Crawford maintains TTM Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTMI#NASDAQ">TTMI</a>) with a Buy and raises the price target from $36 to $50.

TTMI

B. Riley Securities Maintains Buy on TTM Technologies, Raises Price Target to $50

BTCT

BTC Digital Announces Transformative, Strategic Shift To Fully Embrace Ethereum As Core Asset And Operational Foundation; Closes $6M Financing Round, Adds New $1M ETH Position

Truist Securities analyst Matthew Coad maintains Affirm Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) with a Buy and raises the price target from $58 to $72.

AFRM

Truist Securities Maintains Buy on Affirm Holdings, Raises Price Target to $72

Press Releases

Aeva Appoints Leading Technology and Public Markets Investor to its Board of Directors

Aeva Announces First Strategic Customers for High-Precision Industrial Automation Sensors

Aeva Announces Strategic Collaboration and Investment with a Global Fortune 500 Company's Technology Affiliate

Aeva Reports First Quarter 2025 Results

Aeva Selected by World's Largest Commercial Aircraft Manufacturer

Loxo Selects Aeva to Power Autonomous Delivery Vehicles

Aeva Achieves TISAX AL2 Certification, Strengthening Commitment to Automotive Information Security

Aeva to Unveil Vision for the Future of Sensing and Perception at "Aeva Day: Beyond the Beam" Event

Sandia National Laboratories Collaborates with Aeva to Strengthen Security at Nuclear Reactor Sites

Aeva to Accelerate Scaled Production of 4D LiDAR for Autonomous Trucks in Collaboration with Daimler Truck North America

AEVA

Advanced Energy Industries, Inc. - Common Stock

Advanced Energy Indus

PowerFleet

Arlo Technologies

Badger Meter

Cognex

Crane NXT

Daktronics

Evolv Technologies Holdings, Inc. - Class A Common Stock

Evolv Technologies

Faro Technologies

Itron

Keysight Techs

nLight

Mirion Technologies, Inc. Class A Common Stock

Mirion Technologies

Novanta

NAPCO Security Technologies, Inc. - Common Stock

NAPCO Security Techs

OSI Systems

Ouster

PAR Technology

Ralliant

Red Cat Holdings

Teledyne Technologies Incorporated Common Stock

Teledyne Technologies

Trimble

Vontier

Zebra Technologies Corporation - Class A Common Stock

Zebra Technologies

Zepp Health Corporation American depositary shares, each representing sixteen Class A ordinary shares

Zepp Health

Oppenheimer

Roth Capital

Canaccord Genuity

Morgan Stanley

Craig-Hallum

Screenshot 2025-04-07 at 6.49.26 PM

Emerging Markets

Aeva&#39;s Push Into Industrial Market Deepens With Exclusive Deal With Sensys Gatso Australia

Screenshot 2025-03-27 at 7.44.26 PM

Movers & Shakers

Aeva Posts Triple-Digit Q4 Revenue Growth, New Top Passenger OEM Deal And Projects Up To 100% 2025 Revenue Growth Plans

Screenshot 2025-02-05 at 8.51.20 PM

Aeva Demonstrates Vision For Future Of Passenger Vehicle Autonomy With Its Latest Atlas Ultra LiDAR Sensor, New and Expanded Partnerships

Screenshot 2024-12-17 at 6.43.30 PM

Markets

NINOY

Aeva Technologies Gears Up For Scaling of Industrial Automation Sensors As It Expands With Additional Customer

Screenshot 2024-11-12 at 8.16.39 PM

Customer Wins Fuel Triple-Digit Q3 Revenue Growth For Aeva Technologies, Are More Wins On The Horizon?

Screenshot 2024-10-28 at 6.25.40 PM

Tech

Aeva Technologies Inks Multi-Year Deal With The Indoor Lab, Growing Its Commercial Momentum And Increasing Revenue Potential

Screenshot 2024-10-09 at 5.25.23 PM

Aeva Enables Customers To Go Where They Have Never Gone Before – Looking Into Automated Vehicles And Network Effects From An Expanding List Of Customers

Screenshot 2024-09-17 at 7.15.51 PM

NVDA

Why Nvidia, Daimler Truck, Nikon And Top U.S. Security Organization Are Partnering With This AI Chip Stock

Screenshot 2024-09-04 at 6.13.04 PM

The Technology Powering Aeva&#39;s (NYSE: AEVA) Vision For A Safer Autonomous Future And Why It Could Be Game-Changing

Screenshot 2024-08-12 at 6.42.02 PM

Deals With Automotive Companies, Top National Security Organization And More: What Aeva Technologies Has Been Up To This Year To Become A Market Leader

Comments

Aeva Technologies

Noticias

Últimas noticias sobre Aeva Technologies (NASDAQ:AEVA) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL